Cleavage of α-Synuclein by Calpain:  Potential Role in Degradation of Fibrillized and Nitrated Species of α-Synuclein

α-Synuclein (α-syn) is a major protein component of the neuropathological hallmarks of Parkinson's disease and related neurodegenerative disorders termed synucleinopathies. Neither the mechanism of α-syn fibrillization nor the degradative process for α-syn has been elucidated. Previously, we sh...

Full description

Saved in:
Bibliographic Details
Published inBiochemistry (Easton) Vol. 44; no. 21; pp. 7818 - 7829
Main Authors Mishizen-Eberz, Amanda J, Norris, Erin H, Giasson, Benoit I, Hodara, Roberto, Ischiropoulos, Harry, Lee, Virginia M.-Y, Trojanowski, John Q, Lynch, David R
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 31.05.2005
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:α-Synuclein (α-syn) is a major protein component of the neuropathological hallmarks of Parkinson's disease and related neurodegenerative disorders termed synucleinopathies. Neither the mechanism of α-syn fibrillization nor the degradative process for α-syn has been elucidated. Previously, we showed that wild-type, mutated, and fibrillar α-syn proteins are substrates of calpain I in vitro. In this study, we demonstrate that calpain-mediated cleavage near and within the middle region of soluble α-syn with/without tyrosine nitration and oxidation generates fragments that are unable to self-fibrillize. More importantly, these fragments prevent full-length α-syn from fibrillizing. Calpain-mediated cleavage of α-syn fibrils composed of wild-type or nitrated α-syn generate C-terminally truncated fragments that retain their fibrillar structure and induce soluble full-length α-syn to co-assemble. Therefore, calpain-cleaved soluble α-syn inhibits fibrillization, whereas calpain-cleaved fibrillar α-syn promotes further co-assembly. These results provide insight into possible disease mechanisms underlying synucleinopathies since the formation of α-syn fibrils could be causally linked to the onset/progression of these disorders.
Bibliography:istex:9B219DB24F948A9E8707B7B83937DA206D217936
ark:/67375/TPS-2ML1431S-D
This work was supported in part by grants from the National Institute of Aging (to V.M.-Y.L. and H.I.), National Institute of Neurological Disorders and Stroke (to D.R.L.), National Parkinson's Foundation (to D.R.L.), and American Parkinson's Disease Association (to A.J.M.-E.).
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0006-2960
1520-4995
DOI:10.1021/bi047846q